Merck reported solid full-year growth with a 4% increase in sales and a 10% rise in non-GAAP EPS. Management conveyed confidence in maintaining revenue levels despite patent expirations and currency pressures, supported by strategic investments and strong product performance. The positive financial results and proactive outlook are likely to favor the stock in the short term.

[1]